Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Evaluating the rewarding nature of social interactions in laboratory animals.

Trezza V, Campolongo P, Vanderschuren LJ.

Dev Cogn Neurosci. 2011 Oct;1(4):444-58. doi: 10.1016/j.dcn.2011.05.007. Epub 2011 Jun 2. Review.

2.

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Marco EM, García-Gutiérrez MS, Bermúdez-Silva FJ, Moreira FA, Guimarães F, Manzanares J, Viveros MP.

Front Behav Neurosci. 2011 Oct 5;5:63. doi: 10.3389/fnbeh.2011.00063. eCollection 2011.

3.

Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Fattore L, Fratta W.

Front Behav Neurosci. 2011 Sep 21;5:60. doi: 10.3389/fnbeh.2011.00060. eCollection 2011.

4.

Sexually dimorphic effects of cannabinoid compounds on emotion and cognition.

Rubino T, Parolaro D.

Front Behav Neurosci. 2011 Sep 28;5:64. doi: 10.3389/fnbeh.2011.00064. eCollection 2011.

5.

Effects of endocannabinoid system modulation on cognitive and emotional behavior.

Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S.

Front Behav Neurosci. 2011 Sep 13;5:57. doi: 10.3389/fnbeh.2011.00057. eCollection 2011.

6.

The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors.

Terzian AL, Drago F, Wotjak CT, Micale V.

Front Behav Neurosci. 2011 Aug 17;5:49. doi: 10.3389/fnbeh.2011.00049. eCollection 2011.

7.

Adolescent exposure to cannabis as a risk factor for psychiatric disorders.

Rubino T, Zamberletti E, Parolaro D.

J Psychopharmacol. 2012 Jan;26(1):177-88. doi: 10.1177/0269881111405362. Epub 2011 Jul 18. Review.

PMID:
21768160
8.

The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus.

Akirav I.

Front Behav Neurosci. 2011 Jun 23;5:34. doi: 10.3389/fnbeh.2011.00034. eCollection 2011.

9.

Roles of the endocannabinoid system in learning and memory.

Marsicano G, Lafenêtre P.

Curr Top Behav Neurosci. 2009;1:201-30. doi: 10.1007/978-3-540-88955-7_8. Review.

PMID:
21104385
10.

Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats.

Realini N, Vigano' D, Guidali C, Zamberletti E, Rubino T, Parolaro D.

Neuropharmacology. 2011 Feb-Mar;60(2-3):235-43. doi: 10.1016/j.neuropharm.2010.09.003. Epub 2010 Sep 17.

PMID:
20850463
11.

The pleasures of play: pharmacological insights into social reward mechanisms.

Trezza V, Baarendse PJ, Vanderschuren LJ.

Trends Pharmacol Sci. 2010 Oct;31(10):463-9. doi: 10.1016/j.tips.2010.06.008. Epub 2010 Aug 3. Review.

12.

Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine.

Leweke FM, Schneider M.

Int J Neuropsychopharmacol. 2011 Feb;14(1):43-51. doi: 10.1017/S1461145710000842. Epub 2010 Aug 3.

PMID:
20678304
13.

Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia.

Bossong MG, Niesink RJ.

Prog Neurobiol. 2010 Nov;92(3):370-85. doi: 10.1016/j.pneurobio.2010.06.010. Epub 2010 Jul 16. Review.

PMID:
20624444
14.

Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents.

Campolongo P, Trezza V, Ratano P, Palmery M, Cuomo V.

Psychopharmacology (Berl). 2011 Mar;214(1):5-15. doi: 10.1007/s00213-010-1892-x. Epub 2010 Jun 17. Review.

15.

Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative.

de Graaf R, Radovanovic M, van Laar M, Fairman B, Degenhardt L, Aguilar-Gaxiola S, Bruffaerts R, de Girolamo G, Fayyad J, Gureje O, Haro JM, Huang Y, Kostychenko S, Lépine JP, Matschinger H, Mora ME, Neumark Y, Ormel J, Posada-Villa J, Stein DJ, Tachimori H, Wells JE, Anthony JC.

Am J Epidemiol. 2010 Jul 15;172(2):149-59. doi: 10.1093/aje/kwq096. Epub 2010 Jun 9.

16.

[Cognitive abnormalities and cannabis use].

Solowij N, Pesa N.

Rev Bras Psiquiatr. 2010 May;32 Suppl 1:S31-40. Review. Portuguese.

17.

Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat.

Harte LC, Dow-Edwards D.

Neurotoxicol Teratol. 2010 Sep-Oct;32(5):515-24. doi: 10.1016/j.ntt.2010.05.001. Epub 2010 May 9.

18.

The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?

Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F.

Pharmacol Biochem Behav. 2010 Jun;95(4):375-82. doi: 10.1016/j.pbb.2010.03.012. Epub 2010 Mar 27. Review.

PMID:
20347862
19.

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

Petrosino S, Di Marzo V.

Curr Opin Investig Drugs. 2010 Jan;11(1):51-62. Review.

PMID:
20047159
20.

Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission.

Bambico FR, Nguyen NT, Katz N, Gobbi G.

Neurobiol Dis. 2010 Mar;37(3):641-55. doi: 10.1016/j.nbd.2009.11.020. Epub 2009 Dec 5.

PMID:
19969082

Supplemental Content

Support Center